Arcturus Therapeutics Reports Disappointing Earnings
- Disappointing Earnings: Arcturus Therapeutics reported a FY GAAP EPS of -$2.40, missing expectations by $0.24, indicating ongoing challenges in profitability that could undermine investor confidence.
- Revenue Miss: The company generated $82 million in revenue, falling short of expectations by $8.47 million, reflecting weak market demand that may lead to future liquidity issues.
- Operating Expense Reduction: Operating expenses for fiscal year 2025 totaled $158.3 million, a decrease of $89.7 million compared to 2024, showing efforts in cost control, yet insufficient to offset revenue shortfalls.
- Quarterly Expense Analysis: The fourth quarter operating expenses were $38.5 million, down $17.7 million year-over-year, but despite the reduction, the overall financial performance remains poor, potentially impacting future investment decisions.
Trade with 70% Backtested Accuracy
Analyst Views on ARCT
About ARCT
About the author

- Clinical Trial Progress: Arcturus is advancing its ARCT-032 Phase II trial, set to initiate a 12-week study in the first half of 2026, enrolling 20 participants to focus on safety and early clinical benefits, potentially providing critical data for cystic fibrosis treatment.
- Financial Performance Decline: The company reported a year-over-year revenue drop of $70.3 million and a quarterly decline of $15.6 million, primarily due to reduced CSL collaboration activity, reflecting challenges in the commercialization process, although R&D expenses decreased by $83 million, indicating efforts in cost control.
- Strong Cash Position: As of December 31, 2025, the company held $232.8 million in cash and equivalents, with a projected cash runway extending into the second quarter of 2028, providing ample funding for future R&D and clinical trials.
- Regulatory Pathway Clarity: Management plans to hold Type C meetings with regulators in the first half of 2026 to clarify clinical development steps for ARCT-810, ensuring that trial designs for both adult and pediatric populations meet regulatory requirements, thereby facilitating the path to market for key therapeutics.
- Disappointing Earnings: Arcturus Therapeutics reported a FY GAAP EPS of -$2.40, missing expectations by $0.24, indicating ongoing challenges in profitability that could undermine investor confidence.
- Revenue Miss: The company generated $82 million in revenue, falling short of expectations by $8.47 million, reflecting weak market demand that may lead to future liquidity issues.
- Operating Expense Reduction: Operating expenses for fiscal year 2025 totaled $158.3 million, a decrease of $89.7 million compared to 2024, showing efforts in cost control, yet insufficient to offset revenue shortfalls.
- Quarterly Expense Analysis: The fourth quarter operating expenses were $38.5 million, down $17.7 million year-over-year, but despite the reduction, the overall financial performance remains poor, potentially impacting future investment decisions.
- Earnings Announcement Date: Arcturus Therapeutics (ARCT) is set to announce its Q4 earnings on March 3rd after market close, with consensus EPS estimate at -$0.76 and revenue estimate at $14.32 million, indicating financial pressure on the company.
- Historical Performance: Over the past two years, Arcturus has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, demonstrating a degree of reliability in its financial forecasting.
- Estimate Revision Trends: In the last three months, there has been one upward revision and no downward revisions to EPS estimates, suggesting analysts maintain a cautiously optimistic outlook on the company's future performance, possibly reflecting confidence in its products or market strategy.
- Market Reaction Expectations: Despite facing challenges, the market remains attentive to the upcoming earnings report, especially as the current stock price reflects low expectations, potentially offering investors a rebound opportunity.
- Leadership Presentation: Arcturus Therapeutics CEO Joseph Payne will present at the J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco, showcasing the company's latest advancements in mRNA therapeutics, which is expected to attract investor and industry attention.
- Technological Innovation: Arcturus developed KOSTAIVE®, the world's first approved self-amplifying mRNA COVID vaccine, demonstrating its leading position in vaccine development and potentially laying the groundwork for future market expansion.
- Global Collaboration: The company's global collaboration with CSL Seqirus and U.S. BARDA focuses on pandemic flu vaccine development, indicating Arcturus's strategic positioning in addressing public health crises, which may enhance its market competitiveness.
- Diverse Pipeline: Arcturus's pipeline includes RNA therapeutic candidates targeting cystic fibrosis and ornithine transcarbamylase deficiency, showcasing its potential in rare disease treatment, which could provide new revenue streams for the company.

Management Insights: CEO Joseph Payne reported positive interim Phase II data for ARCT-032, an mRNA therapeutic for cystic fibrosis, and ARCT-810 for OTC deficiency, while also noting the indefinite delay of the KOSTAIVE COVID-19 vaccine's US BLA filing due to regulatory changes.
Financial Performance: CFO Andrew Sassine highlighted a significant revenue decline for Q3 2025, with total revenues of $17.2 million, and a net loss of approximately $13.5 million, while emphasizing the company's strong financial position with a cash runway extended into 2028.
Future Outlook: The company plans to initiate a 12-week study for ARCT-032 in the first half of 2026 and is preparing for regulatory meetings regarding pivotal trials for both CF and OTC programs, focusing on safety and efficacy data.
Risks and Concerns: Management acknowledged challenges due to sudden FDA regulatory changes affecting KOSTAIVE, alongside the need for further regulatory alignment for both therapeutic programs, while maintaining a focus on cost control and resource allocation.

Investigation Announcement: Edelson Lechtzin LLP is investigating Arcturus Therapeutics for potential violations of federal securities laws due to allegations of misleading business information provided to investors.
Stock Impact: Following the release of disappointing Phase 2 trial results for its inhaled mRNA therapy ARCT-032, Arcturus's stock plummeted by over 50%, closing at $11.54 per share.
Company Overview: Arcturus Therapeutics focuses on developing mRNA vaccines and therapies, highlighting its role in the biotechnology sector.
Legal Representation: Investors affected by the stock drop or with relevant non-public information are encouraged to contact Edelson Lechtzin LLP for potential legal assistance.






